2011

Regulation of the PMP22 gene through an intronic enhancer

Erin A. Jones  
University of Wisconsin - Madison

Camila Lopez-Anido  
University of Wisconsin - Madison

Rajini Srinivasan  
University of Wisconsin - Madison

Courtney Krueger  
University of Wisconsin - Madison

Li-Wei Chang  
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
Jones, Erin A.; Lopez-Anido, Camila; Srinivasan, Rajini; Krueger, Courtney; Chang, Li-Wei; Nagarajan, Rakesh; and Svaren, John, "Regulation of the PMP22 gene through an intronic enhancer." The Journal of Neuroscience.31,11. 4242-4250. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/221

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Regulation of the PMP22 Gene through an Intrinsic Enhancer

Erin A. Jones, Camila Lopez-Anido, Rajini Srinivasan, Courtney Krueger, Li-Wei Chang, Rakesh Nagarajan, and John Svaren

Program in Cellular and Molecular Biology, Department of Comparative Biosciences, and Waisman Center, University of Wisconsin, Madison, Wisconsin 53705, and Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri 63110

Successful myelination of the peripheral nervous system depends upon induction of major protein components of myelin, such as peripheral myelin protein 22 (PMP22). Myelin stability is also sensitive to levels of PMP22, as a 1.4 Mb duplication on human chromosome 17, resulting in three copies of PMP22, is the most common cause of the peripheral neuropathy Charcot-Marie-Tooth disease. The transcription factor Egr2/Krox20 is required for induction of high level expression of Pmp22 in Schwann cells but its activation elements have not yet been determined. Using chromatin immunoprecipitation analysis of the rat Pmp22 locus, we found a major peak of Egr2 binding within the large intron of the Pmp22 gene. Analysis of a 250 bp region within the largest intron showed that it is strongly activated by Egr2 expression in reporter assays. Moreover, this region contains conserved binding sites not only for Egr2 but also for Sox10, which is also required for Schwann cell development. Our analysis shows that Sox10 is required for optimal activity of the intronic site as well as PMP22 expression. Finally, mouse transgenic analysis revealed tissue-specific expression of this intronic sequence in peripheral nerve. Overall, these data show that Egr2 and Sox10 activity are directly involved in mediating the developmental induction of Pmp22 expression.

Introduction

In the peripheral nervous system, the lipid-rich myelin sheath formed by Schwann cells plays a vital role in axonal function and stability. The myelin sheath is composed of many structural proteins required for the compact structure of myelin and the genes encoding such proteins are highly regulated during development. Genetic defects in the function or level of myelin genes can be detrimental and lead to peripheral neuropathy. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, affecting ~1 in 2500 people. The most common cause of CMT is a 1.4 Mb duplication of human chromosome 17, containing the peripheral myelin protein 22 (PMP22) gene (classified as CMT type 1A), and a deletion of the same region leads to another type of peripheral neuropathy: hereditary neuropathy with liability to pressure palsies (Lupski et al., 1991; Chance et al., 1993; Suter and Scherer, 2003). Pmp22 is a tetraspan protein required for stable myelination (Adlkofer et al., 1995) and a number of rodent models for CMT1A have shown that transgenic overexpression of Pmp22 causes peripheral neuropathy (Huxley et al., 1996; Magyar et al., 1996; Sereda et al., 1996; Huxley et al., 1998; Robertson et al., 2002). Importantly, lowering expression of Pmp22 improves myelination in rodent models of CMT1A (Perea et al., 2001; Sereda et al., 2003; Passage et al., 2004).

Pmp22 is highly upregulated along with other myelin genes in Schwann cells during myelination as well as during remyelination following nerve crush injury (Snipes et al., 1992; Notterpek et al., 1999). Two transgenic studies identified overlapping upstream segments that lead to Schwann cell-specific expression (Maier et al., 2003; Orfali et al., 2005). This upstream region was shown to recapitulate the later expression of endogenous Pmp22 and has been named the late myelination Schwann cell-specific element (LMSE) (Maier et al., 2003). The region(s) responsible for early developmental expression have yet to be identified.

Early growth response 2 (Egr2/Krox20, hereafter referred to as Egr2) is a key regulator of myelin genes during early development (Topilko et al., 1994; Le et al., 2005b; Decker et al., 2006) and is also required for induction of Pmp22 (Nagarajan et al., 2001; Le et al., 2005a). Sox10 is required at several stages of Schwann cell development (Kuhlbrodt et al., 1998; Britsch et al., 2001; Schreiner et al., 2007; Finzsch et al., 2010) but has not been shown to directly regulate Pmp22. Interestingly, Sox10 binds near Egr2 at several loci in myelin genes (Jang et al., 2010) and has been shown to function synergistically with Egr2 at the myelin protein zero (Mpz) locus (Bondurand et al., 2001; Denarier et al., 2005; LeBlanc et al., 2006; Jang and Svaren, 2009). Because of their fundamental role in Schwann cell biology (Svaren and Meijer, 2008), we hypothesize that identifying the Egr2/Sox10 regulated sites will reveal critical regulatory elements within PMP22. Here we use chromatin immunoprecipitation (ChIP) of Egr2 and Sox10 to identify a novel enhancer that drives Schwann cell-specific expression of Pmp22.
Materials and Methods

Chromatin immunoprecipitation. ChIP assays on pooled male and female rat sciatic nerve at postnatal day (P)15 and the S16 cell line were performed as previously described (Jang et al., 2006; Jang and Svaren, 2009), except that the S16 cell line was cross-linked in PBS containing 1% formaldehyde. In addition, the herring sperm DNA in the blocking procedure was omitted in the in vivo ChIP assays. The antibodies used in this study include Egr2 (Covance PRB-236P), Sox10 (Santa Cruz Biotechnology sc-17342X), and control IgG (nonimmune). The antibodies used in this study include Egr2 (Covance PRB-236P), Sox10 (Santa Cruz Biotechnology sc-17342X), and control IgG (nonimmune). The antibodies used in this study include Egr2 (Covance PRB-236P), Sox10 (Santa Cruz Biotechnology sc-17342X), and control IgG (nonimmune).

ChIP analysis using tiled microarrays. To combine ChIP with microarray analysis, amplicons were first generated from ChIP products by whole genome amplification (Sigma). Labeling of the samples with Cy5 (Egr2; Covance) or Cy3 (IgG), followed by microarray hybridization, was performed as described previously (Jang and Svaren, 2009; Jang et al., 2010) by Nimblegen, using a custom microarray designed with isothermic probes staggered by 17 bp over the tiled regions. Coordinates of tiled regions are derived from the Rn4 genome build. Gaps in the tiling representation are expressed from two different promoters, P1 and P2, respectively. The enrichment ratio of Cy5 to Cy3 was plotted on a log2 scale, further processed by baselining all peaks to 1% of the highest peak in the window, and displayed a moving average using a window size of five probes. Peak finding was performed using the NimbleScan (Nimblegen) software, with a false discovery rate of 0.05.

Formaldehyde-assisted isolation of regulatory elements. The formaldehyde-assisted isolation of regulatory elements (FAIRE) assay on the S16 rat Schwann cell line was performed by first rinsing confluent cells with PBS and then cross-linking in PBS containing 1% formaldehyde for 5 min at room temperature (22°C). Glycine was added to 125 mM and incubated for 5 min at room temperature. After washing twice with cold PBS, the cells were harvested, pelleted, and frozen at −80°C. The cell pellet was thawed and sonicated on ice using the Bioruptor (Diagenode) set on high (30 s on, 30 s off; for 20 min) in lysis buffer (150 mM NaCl, 10% glycerol, 50 mM Tris pH 8.0, 2% Triton, 1% SDS, 1 mM EDTA) containing protease inhibitor mixture (5 µl of mixture per milliliter of buffer) (Sigma). The lysate was cleared by centrifugation and unbound DNA was extracted with phenol:chloroform and ethanol precipitated, as previously described (Giresi and Lieb, 2009). The protocol only differed in that NaCl was used in the ethanol precipitation. Twenty percent of the cross-linked chromatin was used as an input control by reversing the cross-links at 65°C overnight before phenol:chloroform extraction. The samples were analyzed using quantitative PCR with the same primer sets used in ChIP (Table 1), performed in duplicate to calculate the relative expression, of a given segment relative to the input control, using the comparative Ct method (Livak and Schmittgen, 2001).

Transfection assay. The B16 (mouse melanoma) cell line was grown and transfected as described previously (Jones et al., 2007; LeBlanc et al., 2007). The reporter constructs contain the following coordinates from human chromosome 17 (hg18Mar. 2006 build in UCSC Genome Browser), cloned upstream of the pGL4 luciferase reporter containing the minimal E1B TATA promoter except the PMP22 −2 kb construct that contains the native PMP22 P2 promoter: PMP22 −7 kb: 15,113,094–15,114,102; PMP22 −2 kb: 15,106,498–15,106,933; PMP22 −5 kb: 15,098,299–15,098,685; PMP22 +5 kb: 15,094,466–15,094,975; PMP22 +11 kb: 15,091,959–15,092,201; PMP22 +16 kb: 15,086,052–15,086,906; PMP22 +24 kb: 15,075,138–15,075,801. The mutations of the PMP22 +11 kb reporter were made using site-directed mutagenesis. The individual Sox10 sites were changed to G at positions 4 and 5 on the CA-rich strand, which has previously been reported to abolish binding (Choo et al., 1997).

siRNA treatment and Western blot analysis. Either siRNA directed toward Sox10 (4390771; Ambion) or a negative siRNA control (Negative control #2, AM4613; Ambion) were transiently transfection S16 cells with the Amaxa system (Lonzza) using the rat neuron nucleofection solution. The transfection constructs were incubated for 48 h before harvesting RNA using Tri Reagent (Ambion), and quantitative PCR was performed in duplicate to calculate the relative expression, using the comparative Ct method (Livak and Schmittgen, 2001).

Lysates from siRNA-treated S16 cells were analyzed by immunoblotting for Sox10 and Pmp22 using a 1:1000 dilution of Sox10 (Santa Cruz Biotechnology) and a 1:1000 dilution of Pmp22 (Abcam). The membranes were probed with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Jackson Laboratories) at a dilution of 1:10,000. Luminescence was detected with ECL Plus (Invitrogen) using the Alpha Innotech Fluorchem HDII imaging system.

Bioinformatic analysis. Regions conserved between humans, rats, and mice in a 40 kb window surrounding the Pmp22 locus were searched for Egr2/Sox10 binding sites using a conserved composite element module previously described (Jones et al., 2007).

Transgenic mice. The transgene used in this study contains the following coordinates from the human genome (Mar. 2006 build in UCSC Genome Browser), cloned upstream of the pGL4 luciferase reporter containing the mouse Hsp68 promoter: chr17: 15,090,965–15,092,611. The transgene was linearized by restriction digestion (KpnI and SalI) and microinjected into the pronucleus of FVB/N one-cell embryos by the University of Wisconsin Waisman Center Rodent Models Core. Relative copy number of each founder was determined by using quantitative PCR to normalize the transgene to an endogenous gene, Hmgher. In P4, P12, and P30, various tissues were collected from both male and female mice for luciferase expression analysis by quantitative reverse transcription PCR.

Immunohistochemistry. Frozen sections of mouse sciatic nerve (6 µm) were fixed in 4% paraformaldehyde in PBS for 15 min at room temperature. After the sections were rinsed with PBS, they were incubated with permeabilizing solution (0.06% Triton X-100 in PBS) for 20 min. They were rinsed three times with PBS and incubated in blocking solution (5% goat serum, 1% BSA in PBS) for 1 h. Sections were incubated with anti-firefly luciferase (Luc-17) mouse monoclonal antibody (1:100; Abcam) for 1 h. They were rinsed three times with PBS and incubated with Alexa-488 secondary antibodies for 1 h. After the sections were rinsed once with PBS, they were incubated with Hoescht 33258 (1:1000; Fisher Scientific) in PBS for 1 min and then rinsed five times with PBS. The sections were mounted on slides using Fluoromount-G mounting medium (Southern Biotech). Immunofluorescent images were visualized via a Nikon C1 confocal microscope.

Results

Identification of Egr2 binding sites in Pmp22

Pmp22 is expressed from two different promoters, P1 and P2, transcribing exon 1A and exon 1B, respectively, which result in

Table 1. Primer sets used in quantitative PCR

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>−7 kb</td>
<td>TCTGAGGCTTCTTCTCCACACGG</td>
<td>TCTCCAGGATAGAGTACAGTT</td>
</tr>
<tr>
<td>−2 kb</td>
<td>AGGGCGGCTCCTGAGACGAA</td>
<td>TTGGTGGCTGTAAGAG</td>
</tr>
<tr>
<td>+5 kb</td>
<td>TTCTCAGGTTAGGAAGATGCTG</td>
<td>AAAGGCGCCTACAGGATA</td>
</tr>
<tr>
<td>+6.5 kb</td>
<td>CCGGCTGTTGAGTCCGATTTT</td>
<td>GCCAGGCGAAAGATACGAC</td>
</tr>
<tr>
<td>+8.5 kb</td>
<td>CCGGAGCCAGACCTCAGAA</td>
<td>AACCATGCCCCATGGTAGT</td>
</tr>
<tr>
<td>+11 kb</td>
<td>CACTGGTCTTGCAGCGGAATT</td>
<td>GAAAACATGTGCACTGTC</td>
</tr>
<tr>
<td>+16 kb</td>
<td>GAGGAGGCTCCATTACAAGT</td>
<td>GCACCACATACAGGCA</td>
</tr>
<tr>
<td>+24 kb</td>
<td>TCCCTCCATAGGAAACCC</td>
<td>TGAAGTATAGGGACAGGAGAT</td>
</tr>
<tr>
<td>Lucferase</td>
<td>GGCTACTGATGGTCGCGGTCTT</td>
<td>TCTCTCAGGAACGGCTAGTC</td>
</tr>
<tr>
<td>End Pmp22</td>
<td>GAGGACAGGGTATACACGATG</td>
<td>GCAACCATGACCCCGGAT</td>
</tr>
<tr>
<td>End Mp22</td>
<td>CCTGCGCTGCATTGTTCC</td>
<td>CATCTGCTGAGCAAGAAGAG</td>
</tr>
<tr>
<td>Hmgcr</td>
<td>GGATGAGCTCCGGTCGCTC</td>
<td>AGAAGAAGCTGTTGCTC</td>
</tr>
</tbody>
</table>
two mRNAs that differ only in their 5’ noncoding region (Bosse et al., 1994; Suter et al., 1994). Both the P1 and P2 promoters are upregulated during myelination, but expression from P1 is Schwann cell-specific, whereas P2 is expressed in other tissues, such as brain, heart, lung, and gut. As myelination progresses, the transcript originating from P1 becomes the predominant form in rodent peripheral nerve, whereas the ratio of P1 to P2 in human peripheral nerve is approximately equal (Suter et al., 1994). Transfection studies of Pmp22 expression have shown that the P1 promoter can drive expression of a reporter in Schwann cells (Suter et al., 1994; Sabérán-Djoneidi et al., 2000; Hai et al., 2001). However, additional regulatory elements are involved since the P1 promoter is unable to independently drive consistent expression in peripheral nerve of transgenic mice (Maier et al., 2003).

Since Egr2 activates Pmp22 expression (Nagarajan et al., 2001; Le et al., 2005a), we sought to identify Egr2 binding sites as a means to discover critical Pmp22 enhancer elements. We therefore adapted Egr2 ChIP assays in the S16 rat Schwann cell line for analysis with a tiled microarray (ChIP-chip) containing 200 kb surrounding the rat Pmp22 gene (Fig. 1A). The S16 cell line expresses high levels of myelin genes, including Pmp22, comparable to those in myelinating Schwann cells (Hai et al., 2002). Egr2 ChIP DNA was cobybridized to the custom array along with control IgG ChIP DNA, and the fluorescence ratio was plotted relative to the position within the Pmp22 locus. The results show a major peak at +11 kb (relative to the translation start site) within the largest intron of the Pmp22 gene, along with some more minor peaks distributed throughout the gene.

Several sites with various levels of Egr2 binding were chosen for further analysis (Fig. 1A, arrows). The site at −7 kb is within a larger region previously shown to drive Schwann cell-specific expression in mice (Maier et al., 2003; Orfali et al., 2005). The −2 kb region is just upstream of the P2 promoter, expressing exon 1b. Several intronic sites in uncharacterized regions of Pmp22 were also chosen for further analysis, including the major peak at +11 kb. Egr2 binding at these sites was validated by quantitative PCR analysis of independent ChIP samples from the S16 cell line, revealing high levels of Egr2 at +11 kb relative to a control immunoprecipitation (Fig. 1B). Moreover, we also performed in vivo ChIP assays using P15 rat sciatic nerve, which is an optimal site for detection of Egr2 binding by ChIP (Jang et al., 2006; Mager et al., 2008; Jang and Svennen, 2009). The in vivo ChIP assay demonstrated a significant level of binding at +11 kb, consistent with the ChIP assays in the S16 cell line (Fig. 1C).

Many of the minor peaks in the ChIP–chip analysis do not exhibit significant Egr2 binding above background in quantitative PCR analysis of ChIP samples from S16 cells or in vivo. The +11 kb region appears to be the predominant region for Egr2 binding during myelination.

**Figure 1.** ChIP–chip analysis of the Pmp22 locus. A, ChIP–chip analysis of Egr2 binding was performed in S16 rat Schwann cells with a custom tiled array containing the Pmp22 locus. The enrichment ratio of Cy5-labeled Egr2 ChIP DNA to Cy3-labeled IgG ChIP DNA was plotted on a log, scale and further processed by baselining to 1% of the highest peak and displayed a five-point moving average. Peak analysis was performed (NimbleScan) with a false discovery rate of 0.05. A significant peak at +11 kb was observed in two independent Egr2 ChIP–chip experiments and the peak at +6.5 kb was only detected in one of the two experiments. Below, Noncoding exons (white boxes), coding exons (gray boxes), alternative transcription start sites (P1 and P2), and regions chosen for further analysis (downward arrows) with their distance relative to the translation start site are indicated. B, S16 ChIP assays for Egr2 binding were analyzed by quantitative PCR with indicated primer sets. The graph indicates fold enrichment at each site relative to an IgG control ChIP assay. Error bars represent the SD of two technical replicates. The fold enrichment of the signal at the +11 kb site was at least ninefold in three independent experiments. C, In vivo ChIP assays for Egr2 binding were performed using pooled P15 rat sciatic nerve and analyzed by quantitative PCR using the same primer sets as in B. Error bars represent the SD of two technical replicates. The fold enrichment of the signal at the +11 kb site was at least eightfold in three independent experiments.

**Activation of PMP22-derived segments in reporter assays**

To determine whether Egr2-bound regions have enhancer activity, many of the regions chosen for further analysis in the ChIP assay were tested for their response to Egr2 expression in a luciferase reporter assay. Segments were cloned upstream of a minimal TATA promoter driving luciferase except −2 kb, which contains the P2 promoter (Fig. 2A, arrows). As many of these segments contained conserved sequences, the homologous human sequences were used to create the reporter vectors.

The reporters were tested in the B16/F10 melanoma cell line, which expresses Sox10 (Kamaraju et al., 2002) but not Egr2 (Slutsky et al., 2003), for activation by cotransfection of an Egr2 expression construct. The +11 kb reporter from the largest intron was highly activated in response to Egr2, whereas the other six reporters were not strongly activated. The +11 kb region also showed the strongest Egr2 binding in the ChIP assays (Fig. 1), indicating that Egr2 binding is correlated with enhancer activity in this assay.

**Identification of functional Sox10 and Egr2 sites in the +11 kb enhancer**

Analysis of the human +11 kb element revealed four putative Egr2 sites and one putative dimeric Sox10 site, which are variably conserved in the rat, mouse, and human genomes (Fig. 2B). The +11 kb reporter construct used above was mutated to test the importance of these sites in Egr2 activation. The Egr2 sites were
mutated to A at position 6 of the G-rich strand, which has previously been shown to abolish binding (Choo et al., 1997). When all four sites were mutated, the Egr2 activation was abolished (Fig. 3A). To determine which of the four Egr2 sites are functional, the Egr2 sites were each mutated individually (Fig. 3B). Transfection analysis of the resulting promoter constructs showed that mutating Egr2 site 2 had the largest effect, whereas reporter activity was relatively unimpaired by mutation of sites 1 or 3. There was an approximate 50% decrease with mutation of site 4.

Subsequently, reporter constructs were created in which all but one of the putative Egr2 sites were mutated (Fig. 3C). In this series, the construct containing Egr2 site 2 was most highly activated, yielding a 179-fold activation, which is approximately one-fifth of the activity of the wild-type element. Egr2 sites 3 and 4 support a lower level of activation in this assay, suggesting that Egr2 site 2 is most conserved, especially at the bases that are most critical for binding. Although Egr2 site 4 in the human sequence would be predicted to be a high affinity site, it is less well conserved in rat and mouse.

To determine whether the Sox10 site is functional, the adenines at positions 4 and 5 of the CA rich strand (AAACANG) were mutated to G in both sides of the dimeric Sox10 site, which has previously been shown to disrupt Sox10 binding (Bondurand et al., 2001). Mutating the Sox10 sites lowered the Egr2-dependent activation, suggesting that Egr2 activation requires Sox10 binding at this site (Fig. 3A). Although the B16/F10 cell line expresses Sox10, cotransfection of 100 ng of Sox10 expression plasmid further activated the +11 kb reporter 14-fold ± 2.4. The Sox10 mutation decreased Sox10 activation of the +11 kb reporter to 1.8-fold ± 0.3, suggesting that this is a functional Sox10 site and the +11 kb element is dependent on both Egr2 and Sox10 for activation.
Sox10 regulates Pmp22

Since the dependence of Pmp22 expression on Sox10 activity has not been tested previously, we examined Pmp22 levels in S16 Schwann cells treated with siRNA directed against Sox10 (Fig. 4A). At 48 h after transfection, quantitative reverse transcriptase (RT)-PCR analysis revealed a significant decrease in Sox10 mRNA levels, and Western analysis showed a decrease in Sox10 protein (Fig. 4A,B). This reduction was observed for both Pmp22 transcripts using primer sets specific for exons 1a and 1b. Similar results were obtained using two independent siRNAs directed toward Sox10 (data not shown).

Previous work has shown that Sox10 is required for expression of Egr2 in myelinating Schwann cells (Ghislain and Charnay, 2006; Finzsch et al., 2010; Reiprich et al., 2010). Consistent with these findings, Egr2 levels were reduced by Sox10 depletion in the S16 cell line. Since the effect of Sox10 on Pmp22 expression could be mediated indirectly through regulation of Egr2, ChIP assays were used to detect Sox10 binding within the Pmp22 locus (Fig. 4C,D). ChIP assays were performed using an antibody directed against Sox10 in both the S16 rat Schwann cell line and in vivo using rat sciatic nerve. The Sox10 ChIP assay was performed using the same primer sets used to detect Egr2 occupancy and revealed that Sox10 coincides with Egr2 binding at the +11 kb site. However, we also observed Sox10 binding at other sites across Pmp22, with the highest amount of Sox10 binding at the −7 kb site that resides within the previously defined LMSE (Maier et al., 2003).

To test the specificity of the Sox10 ChIP assays, the same assay was also performed in S16 cells in which Sox10 levels were depleted by Sox10 siRNA (Fig. 4C). For the sites examined, the percentage recovery was severely reduced, indicating that the ChIP assays detected specific binding of Sox10 to those sites. Accordingly, the Sox10 antibody detects a single band in the Western blot (Fig. 4B).

Egr2 and Sox10 bound regions are in regions of open chromatin

To further test for common characteristics of enhancer elements, FAIRE was used in S16 cells to identify areas of open chromatin (Giresi et al., 2007), which are typically present in regulatory regions (Felsenfeld and Groudine, 2003). This technique relies on the fact that enhancers often reside in nucleosome-depleted regions. Because DNA is most efficiently cross-linked to histones by formaldehyde, phenol extraction of protein-cross-linked DNA results in preferential enrichment of nucleosome-free regions of the genome. The FAIRE analysis shows that there is selective enrichment of DNA surrounding the −7 kb, −2 kb, and +11 kb regions, consistent with areas of open chromatin (Fig. 5). We expected the −2 kb region to have open chromatin because it is directly upstream of the active P2 promoter (Hai et al., 2002), and FAIRE specifically enriches for nucleosome-free regions at promoters of highly transcribed genes (Hogan et al., 2006). Similar regions of open chromatin were found in a previous study from our lab using in vivo FAIRE from P15 rat sciatic nerve (Jang et al., 2010). The regions of open chromatin at −7 kb and +11 kb are consistent with the hypothesis that these are enhancer elements.

Sequence analysis of Egr2 and Sox10 sites in the Pmp22 locus

The Pmp22 locus was also screened for conserved occurrences of a composite matrix containing consensus sequences for both Egr2 and dimeric Sox10 sites. Using a composite matrix provided a more reliable prediction of enhancer elements in myelin genes than identification of Egr2 or Sox10 sites alone (Jones et al., 2007). Performing this screen for composite sites conserved in mouse, rat, and human PMP22 genes identified three regions that contain the Sox/Egr2 binding module (Table 2). One region is at the +11 kb site, a second is at the −7 kb site, and the third is at +45 kb in relation to the translation start site and far downstream of the 3′ end of Pmp22. The +45 kb Egr2 sequence has an A at position 6 of the G-rich strand, which has previously been shown to abolish binding (Choo et al., 1997), making this a poor site. Our data have shown that the intronic enhancer at +11 kb is regulated by Egr2 and Sox10, again showing that this composite matrix has predictive value. We did observe high levels of Sox10 binding at the −7 kb sites, and there was a small response of this region to Sox10 in transfection studies (data not shown). However, reporter studies of this site failed to show any response to Egr2, and the ChIP data showed relatively low binding of Egr2. As mentioned, the −7 kb region used here represents only a small portion of a larger region that has been shown previously to drive Schwann cell-specific expression (Maier et al., 2003; Orfali et al., 2005), so it is possible that Egr2-responsive elements are located elsewhere within this region.
Table 2. Evolutionarily conserved SOX/EGR2 modules found in mouse Pmp22 phenol extraction of cross-linked chromatin. The percentage recovery was calculated relative to regions chosen for FAIRE analysis, in which areas of open chromatin are selectively enriched by tissue-specific expression of a lacZ reporter in transgenic mice. Sites are numbered relative to the mouse Pmp22 promoter that are critical to its regulation.

<table>
<thead>
<tr>
<th>Name of site</th>
<th>SOX position</th>
<th>SOX score</th>
<th>SOX dimer spacing (bp)</th>
<th>EGR position</th>
<th>EGR score</th>
<th>Distance to SOX site</th>
</tr>
</thead>
<tbody>
<tr>
<td>−7 kb</td>
<td>−6533</td>
<td>9.54</td>
<td>4</td>
<td>−6470</td>
<td>5.52</td>
<td>63</td>
</tr>
<tr>
<td>+11 kb</td>
<td>11567</td>
<td>8.07</td>
<td>4</td>
<td>11492</td>
<td>4.72</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>11553</td>
<td></td>
<td></td>
<td>11689</td>
<td>6.81</td>
<td>122</td>
</tr>
<tr>
<td></td>
<td>49424</td>
<td>8.51</td>
<td>4</td>
<td>49446</td>
<td>5.28</td>
<td>22</td>
</tr>
</tbody>
</table>

Sites within a 100 kb window surrounding the mouse Pmp22 locus (chr11:62,909,000–63,099,000, mm9) were predicted using a conserved composite matrix described previously (Jones et al., 2007). Such sites conserved in human and rat genomes are shown. The sites are numbered relative to the mouse Pmp22 P1 promoter.

The +11 kb region drives tissue-specific expression

The LMSE region upstream of Pmp22, comprising approximately 3.5 kb surrounding the −7 kb element, has been shown to drive tissue-specific expression of a lacZ reporter in transgenic mice late in development (Maier et al., 2003). We hypothesized that the +11 kb element could also drive tissue-specific expression and may account for earlier developmental expression of Pmp22. Transgenic injections were performed with the region surrounding the +11 kb element driving a luciferase reporter with the Hsp68 promoter (Fig. 6A). This promoter has very low levels of expression in peripheral nerve and it has been used extensively to test tissue specificity of regulatory elements in transgenic experiments (Kothary et al., 1988; Rossant et al., 1991; Mandemakers et al., 2000; Forghani et al., 2001; Maier et al., 2002, 2003; Orfali et al., 2005). However, Maier et al. indicated that other regions of Pmp22 are likely required, particularly for the early induction of Pmp22 during myelination. Using ChIP–chip analysis of 200 kb surrounding the Pmp22 gene, we found a novel +11 kb intronic enhancer driven by both Egr2 and Sox10. Because the region upstream of Pmp22 has been shown to drive Schwann cell-specific expression late in development, we speculated that the +11 kb enhancer may account for the earlier expression of Pmp22, and the transgenic data are consistent with this hypothesis. Since ChIP assays detect higher levels of Egr2 binding at +11 kb, a possible explanation for the earlier expression of the +11 kb element in transgenic studies is that Egr2 has a higher affinity for this site. Therefore, Egr2 must accumulate to higher levels in myelinating Schwann cells to activate the upstream enhancer. However, these elements probably do not act in an isolated manner and it is likely that temporal regulation depends upon looping-mediated interactions between these two enhancers (and perhaps others) and the promoters that set the critical level of Pmp22 transcription.

In addition to sciatic nerve and liver, we also sampled heart, lung, kidney, spleen, and brain from lines D and E, and used quantitative RT-PCR to detect luciferase mRNA in these tissues (Fig. 6D). Line E had very high expression in the lung, possibly due to insertion near an active enhancer element in lung. Expression in the sciatic nerve suggests that this element is important to Schwann cell expression of Pmp22 and the residual activity of this +11 kb element in other tissues suggests that it may play a role in the basal level of Pmp22 mRNA expression observed in other tissues (Suter et al., 1994). Finally, expression of the luciferase protein was observed by immunohistochemistry in sciatic nerve of a P50 mouse from line E (Fig. 6E).

Discussion

The activation of Pmp22 is regulated spatially and temporally to achieve the critical levels of Pmp22 required for proper myelin formation. Previous studies have characterized the regions upstream of the Pmp22 promoter that are critical to its regulation (Suter et al., 1994; Sabéran-Djoneidi et al., 2000; Hai et al., 2001; Maier et al., 2002, 2003; Orfali et al., 2005). However, Maier et al. indicated that other regions of Pmp22 are likely required, particularly for the early induction of Pmp22 during myelination. Using ChIP–chip analysis of 200 kb surrounding the Pmp22 gene, we found a novel +11 kb intronic enhancer driven by both Egr2 and Sox10. Because the region upstream of Pmp22 has been shown to drive Schwann cell-specific expression late in development, we speculated that the +11 kb enhancer may account for the earlier expression of Pmp22, and the transgenic data are consistent with this hypothesis. Since ChIP assays detect higher levels of Egr2 binding at +11 kb, a possible explanation for the earlier expression of the +11 kb element in transgenic studies is that Egr2 has a higher affinity for this site. Therefore, Egr2 must accumulate to higher levels in myelinating Schwann cells to activate the upstream enhancer. However, these elements probably do not act in an isolated manner and it is likely that temporal regulation depends upon looping-mediated interactions between these two enhancers (and perhaps others) and the promoters that set the critical level of Pmp22 transcription.

Although the −7 kb region was not activated by Egr2 in reporter assays, it should be noted that the sequences that we used represent only a fraction of the previously reported 3.5 kb LMSE region (Maier et al., 2003), possibly explaining why it was not activated in our Egr2 activation assays. In the ChIP assays, we observed a high level of Sox10 binding at −7 kb, whereas Egr2 binding was higher at +11 kb. In fact, although the −7 kb reporter did not respond to Egr2 in the transfection assay, it responded slightly to Sox10 (data not shown). This leads us to speculate that the varying strengths of Egr2 and Sox10 binding establish temporally regulated binding at each Pmp22 enhancer and leads to more sensitive regulation of Pmp22 during development.

Previous work has shown that Egr2 is required for Pmp22 expression (Nagarajan et al., 2001; Le et al., 2005a), but investigating the role of Sox10 in regulation of Pmp22 in myelinating Schwann cells has been complicated because of the early embryonic lethality of Sox10-null mice (Britsch et al., 2001). Hypomorphic alleles and a conditional knock-out of Sox10 have been generated that permit further differentiation of Schwann cells (Schreiner et al., 2007; Finzsch et al., 2010), but these fail to activate Egr2 expression, consistent with previous studies showing that Sox10 binds to the myelinating Schwann cell enhancer of the Egr2/Krox20 gene (Ghislain and Charnay, 2006; Reiprich et al., 2010). The RNAi-mediated depletion of Sox10 in S16 cells...
similarly reduced Egr2 levels, indicating that Sox10 depletion may indirectly affect Pmp22 expression through downregulation of Egr2. However, direct regulation of Pmp22 by Sox10 is supported by the detection of Sox10 binding in the Pmp22 locus by ChIP assays, and the observed effects of mutating the Sox10 site in the +11 kb enhancer.

Both ascorbic acid and progesterone antagonists lower Pmp22 levels and improve the phenotype in mouse and rat models of CMT1A (Sereda et al., 2003; Passage et al., 2004). Ascorbic acid affects Pmp22 through inhibition of the cAMP pathway (Kaya et al., 2007) and although it has not been shown directly that Egr2 is involved, Egr2 is induced through the cAMP pathway (Zorick et al., 1996). In the case of progesterone antagonists, it also has not been shown directly to involve Egr2 and Sox10, but progesterone induces both Egr2 and Sox10 (Guennoun et al., 2001; Magnaghi et al., 2007) and they are presumably downregulated with progesterone antagonist treatment. Although it has not been shown whether Egr2 or Sox10 mediate the effects of ascorbic acid or progesterone antagonists, our data support a model of Pmp22 regulation, at least in part, through Egr2 and Sox10.

Other studies describe the interaction of Egr2 and Sox10 in regulatory elements in the Connexin 32 and Mbp genes (Bon durand et al., 2001; Denarier et al., 2005), and Egr2 and Sox10 bind cooperatively at an intronic regulatory element in Mpz and physically interact (LeBlanc et al., 2007). In addition, ChIP–chip analysis of a larger set of myelin genes revealed that Sox10 colocalizes with Egr2 more often than would be expected by chance (Jang et al., 2010). Reporter analysis of the intrinsic element in Pmp22 revealed that Egr2 activation of this element is dependent upon Sox10. Furthermore, Pmp22 activation is sensitive to a dominant mutant of Egr2 (Nagarajan et al., 2001), which disrupts cooperative interactions between Egr2 and Sox10 (LeBlanc et al., 2007), suggesting that Egr2 and Sox10 are working cooperatively at Pmp22. We previously proposed a composite matrix of Egr2 and Sox10 binding sites as a means to predict regulatory elements in myelin genes (Jones et al., 2007). Interestingly, application of this matrix to the Pmp22 gene identified only three such sites in which Egr2 and Sox10 binding sites are conserved. One was within the LMSE segment upstream of the gene, and the other coincided with the intron regulatory element that we have characterized. Overall, these data are consistent with a model of Egr2 and Sox10 binding in myelin loci, where both Egr2 and Sox10 are required for full activation of the loci where they bind.

The upstream and intragenic binding of Egr2 and Sox10 is similar to the enhancer pattern found in another highly expressed myelin gene, Mpz (Jang and Svaren, 2009). Finding this pattern leads us to hypothesize that this is a common mechanism of transcriptional activation. Perhaps these sites interact, altering the chromatin architecture and leading to transcriptional activation through an unknown mechanism. Enhancer interaction may be promoted by the DNA bending properties of Sox10 (Werner et al., 1995; Peirano and Wegner, 2000). Further work will be needed to determine whether these elements interact in vivo.

Although we have focused on Pmp22 transcriptional regulation, there is a large body of work on Pmp22 posttranscriptional regulation. Pmp22 protein is highly regulated and is turned over quickly by the proteasome (Pareek et al., 1997; Notterpek et al., 1999). A point mutation or extra copies of Pmp22 lead to an accumulation of the protein that overwhelms the degradation pathway, leading to the CMT1A phenotype (Fortun et al., 2003, 2006). In addition, recent studies of micro-RNAs have found that, whereas Pmp22 mRNA is expressed in other tissues in addition to peripheral nerve, protein expression is much more selective because of the effects of micro-RNAs (Lau et al., 2008; Verrier et al., 2009). The expression of our transgenic construct in tissues other than sciatic nerve may reflect the lack of known micro RNA binding sites in the Pmp22 3' UTR.

Our finding of a new enhancer in PMP22 has significant therapeutic implications for peripheral neuropathies. It is possible that noncoding mutations in regulatory elements may be associated with human peripheral neuropathies. In addition, regulatory element polymorphisms may be a factor that contributes to the range of severity experienced by CMT1A patients. Finally, identification of key regulatory elements in the PMP22 gene is
expected to contribute toward development of novel treatment strategies for CMT1A by facilitating identification of compounds that reduce PMP22 expression.

References


